8-K: Tonix Pharmaceuticals Presents Positive TNX-102 SL Data for Fibromyalgia Treatment at International Congress

Tonix Pharmaceuticals highlights durable pain reduction with TNX-102 SL in fibromyalgia patients at the 7th International Congress on Controversies in Fibromyalgia.

Summary

• Tonix Pharmaceuticals presented data on TNX-102 SL for fibromyalgia treatment at the 7th International Congress on Controversies in Fibromyalgia.
• TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery.
• The FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia.
• If approved, TNX-102 SL could be the first new drug for treating fibromyalgia in more than 15 years and the first in a new class of non-opioid analgesics.
• Two Phase 3 studies showed statistically significant improvement in reducing fibromyalgia pain with TNX-102 SL.
• TNX-102 SL targets non-restorative sleep, which is linked to reduced pain in fibromyalgia patients.
• The sublingual formulation reduces the formation of norcyclobenzaprine compared to oral delivery.
• Fibromyalgia affects over 10 million adults in the U.S., with symptoms including chronic pain, non-restorative sleep, and fatigue.
• TNX-102 SL is designed for chronic use and is a potent antagonist at four post-synaptic receptors involved in regulating sleep.
• Patents for TNX-102 SL's eutectic composition provide market protection into 2034.
• The RESILIENT study showed a statistically significant reduction in daily pain compared to placebo (p = 0.00005).
• The most common adverse event was tongue or mouth numbness at the administration site.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and regulatory progress for TNX-102 SL, suggesting a favorable outlook for the company. The potential for a new treatment option for fibromyalgia is also a positive factor.

Positives

• TNX-102 SL showed statistically significant and durable pain reduction in two Phase 3 studies.
• The FDA has assigned a PDUFA goal date of August 15, 2025, indicating regulatory progress.
• TNX-102 SL could be the first new fibromyalgia treatment in over 15 years and a new class of non-opioid analgesic.
• The sublingual formulation reduces the formation of the active metabolite norcyclobenzaprine.
• The RESILIENT study demonstrated a highly statistically significant improvement in mean weekly pain scores over placebo at Week 14 (p = 0.00005).
• TNX-102 SL was generally well-tolerated in clinical trials.
• Patents provide market protection for TNX-102 SL's eutectic composition into 2034.

Negatives

• The RALLY study missed its primary endpoint.
• TNX-102 SL is associated with administration site reactions such as oral numbness.
• The drug is still investigational and requires FDA approval.
• There are risks related to obtaining FDA clearances or approvals and noncompliance with FDA regulations.

Risks

• Failure to obtain FDA approval for TNX-102 SL.
• Risks related to successfully marketing any of Tonix's products.
• Uncertainties of patent protection and litigation.
• Dependence upon third parties for research and development efforts.
• Substantial competition in the pharmaceutical market.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company anticipates a decision from the FDA regarding marketing authorization for TNX-102 SL by the PDUFA goal date of August 15, 2025. Tonix is focused on advancing TNX-102 SL for the management of fibromyalgia.

Management Comments

• 'Since fibromyalgia is a chronic pain condition, medicines to treat fibromyalgia need to provide durable benefits,' said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
• 'TNX-102 SL is designed as a bedtime treatment to target non-restorative sleep, which in turn has shown to result in reduced pain,' Dr. Lederman continued.

Industry Context

The announcement highlights the need for new and effective treatments for fibromyalgia, a condition affecting millions. The current market has limited options, and TNX-102 SL aims to address this unmet need with a novel approach targeting non-restorative sleep.

Comparison to Industry Standards

• Oral cyclobenzaprine has shown only transient (one month) activity in fibromyalgia, but not durable (three months) activity in reducing fibromyalgia pain.
• Unlike oral cyclobenzaprine, TNX-102 SL has demonstrated statistically significant, durable activity (3 months) in reducing fibromyalgia pain in two Phase 3 studies.
• The company references Flexeril and Amrix as oral formulations of cyclobenzaprine indicated for short term (2 3 weeks) treatment of muscle spasm, while TNX 102 SL is designed for long term use in fibromyalgia.

Stakeholder Impact

• Positive impact on fibromyalgia patients if TNX-102 SL is approved, providing a new treatment option.
• Potential benefit to shareholders if the drug is successfully commercialized.
• May impact physicians treating fibromyalgia with a new therapeutic option.

Next Steps

• The company awaits the FDA's decision on marketing authorization for TNX-102 SL, expected by August 15, 2025.
• The company plans to publish the results of the RESILIENT study in a journal later this year.

Key Dates